Parallelized sample processing and library prep
US-12097501-B2 · Sep 24, 2024 · US
Inhibition of chemokine CCL7 or receptor CCR3 of same for the treatment and diagnosis of prostate cancer
US10401365B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10401365-B2 |
| Application number | US-201515318777-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 16, 2015 |
| Priority date | Jun 16, 2014 |
| Publication date | Sep 3, 2019 |
| Grant date | Sep 3, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention concerns an inhibitor of the expression of chemokine CCL7 or an inhibitor of the expression of the receptor CCR3 or an inhibitor of CCL7/CCR3 interaction for the use of same to prevent or treat the extension of prostate cancer outside the prostatic capsule in a subject. The invention also concerns a method for determining the degree of aggressiveness of a prostate cancer tumor in a subject suffering from prostate cancer, comprising a step of determining the concentration or level of expression of the receptor CCR3 in a sample of prostate tumor cells obtained from said subject.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating or inhibiting adipocyte-mediated migration of prostate cancer outside the prostatic capsule in a subject in need thereof comprising administering to the subject an inhibitor of a CCL7/CCR3 interaction consisting of an organic molecule selected from the group of the compounds in Table 7. 2. The method of claim 1 , wherein the inhibitor of the CCL7/CCR3 interaction comprises a CCR3 antagonist. 3. The method of claim 1 , wherein the organic molecule is the compound having formula DLI. 4. The method of claim 1 , wherein the subject is an adult male who is obese and/or has abundant periprostatic adipose tissue (PPAT). 5. The method of claim 2 , wherein the subject is an adult male who is obese and/or has abundant periprostatic adipose tissue (PPAT). 6. The method of claim 3 , wherein the subject is an adult male who is obese and/or has abundant periprostatic adipose tissue (PPAT).
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
involving compounds localised on the membrane of tumour or cancer cells · CPC title
- G01N33/57555Primary
of the prostate · CPC title
Staging of a disease; Further complications associated with the disease · CPC title
Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10401365B2 cover?
- The invention concerns an inhibitor of the expression of chemokine CCL7 or an inhibitor of the expression of the receptor CCR3 or an inhibitor of CCL7/CCR3 interaction for the use of same to prevent or treat the extension of prostate cancer outside the prostatic capsule in a subject. The invention also concerns a method for determining the degree of aggressiveness of a prostate cancer tumor in …
- Who is the assignee on this patent?
- Univ Toulouse 3 Paul Sabatier, Centre Nat Rech Scient, Ct Hospitalier Universitaire Toulouse, and 2 more
- What technology area does this patent fall under?
- Primary CPC classification G01N33/57555. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).